S&P 500   3,167.98 (+0.40%)
DOW   26,376.67 (+1.12%)
AAPL   380.87 (-0.27%)
MSFT   205.46 (-0.78%)
FB   237.12 (-0.79%)
GOOGL   1,500.39 (-0.78%)
AMZN   3,053.15 (-1.64%)
NVDA   401.66 (-0.11%)
BABA   246.20 (-2.17%)
AMD   53.51 (-0.15%)
T   29.93 (+0.54%)
DIS   117.33 (+0.94%)
NFLX   509.79 (-2.99%)
BAC   23.93 (-1.12%)
S&P 500   3,167.98 (+0.40%)
DOW   26,376.67 (+1.12%)
AAPL   380.87 (-0.27%)
MSFT   205.46 (-0.78%)
FB   237.12 (-0.79%)
GOOGL   1,500.39 (-0.78%)
AMZN   3,053.15 (-1.64%)
NVDA   401.66 (-0.11%)
BABA   246.20 (-2.17%)
AMD   53.51 (-0.15%)
T   29.93 (+0.54%)
DIS   117.33 (+0.94%)
NFLX   509.79 (-2.99%)
BAC   23.93 (-1.12%)
S&P 500   3,167.98 (+0.40%)
DOW   26,376.67 (+1.12%)
AAPL   380.87 (-0.27%)
MSFT   205.46 (-0.78%)
FB   237.12 (-0.79%)
GOOGL   1,500.39 (-0.78%)
AMZN   3,053.15 (-1.64%)
NVDA   401.66 (-0.11%)
BABA   246.20 (-2.17%)
AMD   53.51 (-0.15%)
T   29.93 (+0.54%)
DIS   117.33 (+0.94%)
NFLX   509.79 (-2.99%)
BAC   23.93 (-1.12%)
S&P 500   3,167.98 (+0.40%)
DOW   26,376.67 (+1.12%)
AAPL   380.87 (-0.27%)
MSFT   205.46 (-0.78%)
FB   237.12 (-0.79%)
GOOGL   1,500.39 (-0.78%)
AMZN   3,053.15 (-1.64%)
NVDA   401.66 (-0.11%)
BABA   246.20 (-2.17%)
AMD   53.51 (-0.15%)
T   29.93 (+0.54%)
DIS   117.33 (+0.94%)
NFLX   509.79 (-2.99%)
BAC   23.93 (-1.12%)
Log in

NASDAQ:ACORAcorda Therapeutics Stock Price, Forecast & News

$0.69
-0.01 (-1.43 %)
(As of 07/14/2020 11:32 AM ET)
Add
Compare
Today's Range
$0.66
Now: $0.69
$0.72
50-Day Range
$0.70
MA: $0.79
$1.07
52-Week Range
$0.70
Now: $0.69
$7.13
Volume46,879 shs
Average Volume1.43 million shs
Market Capitalization$33.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Read More
Acorda Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$192.41 million
Cash Flow$4.60 per share
Book Value$6.47 per share

Profitability

Net Income$-272,970,000.00
Net Margins-131.45%

Miscellaneous

Employees474
Market Cap$33.11 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

How has Acorda Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Acorda Therapeutics' stock was trading at $1.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACOR stock has decreased by 31.7% and is now trading at $0.69. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Acorda Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acorda Therapeutics.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Acorda Therapeutics.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) issued its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.05. The biopharmaceutical company earned $28.10 million during the quarter, compared to analyst estimates of $39.34 million. Acorda Therapeutics had a negative net margin of 131.45% and a negative return on equity of 19.83%. View Acorda Therapeutics' earnings history.

What price target have analysts set for ACOR?

6 analysts have issued 1-year target prices for Acorda Therapeutics' shares. Their forecasts range from $1.40 to $12.00. On average, they anticipate Acorda Therapeutics' share price to reach $7.07 in the next twelve months. This suggests a possible upside of 924.2% from the stock's current price. View analysts' price targets for Acorda Therapeutics.

Has Acorda Therapeutics been receiving favorable news coverage?

Media stories about ACOR stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acorda Therapeutics earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Acorda Therapeutics.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 10,390,000 shares, an increase of 23.8% from the June 15th total of 8,390,000 shares. Based on an average trading volume of 1,920,000 shares, the short-interest ratio is currently 5.4 days. Approximately 22.0% of the shares of the company are short sold. View Acorda Therapeutics' Current Options Chain.

Who are some of Acorda Therapeutics' key competitors?

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include InterDigital Wireless (IDCC), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Applied Materials (AMAT), Intel (INTC), Novavax (NVAX), Western Digital (WDC), salesforce.com (CRM) and FTS International (FTSI).

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the following people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
  • Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
  • Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64)

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $0.69.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $33.11 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is www.acorda.com.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.